KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Accumulated Expenses (2016 - 2026)

Pacira BioSciences has reported Accumulated Expenses over the past 17 years, most recently at $85.0 million for Q1 2026.

  • For Q1 2026, Accumulated Expenses rose 6.1% year-over-year to $85.0 million; the TTM value through Mar 2026 reached $85.0 million, up 6.1%, while the annual FY2025 figure was $95.6 million, 19.32% up from the prior year.
  • Accumulated Expenses for Q1 2026 was $85.0 million at Pacira BioSciences, down from $95.6 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $95.6 million in Q4 2025 and troughed at $56.2 million in Q2 2023.
  • A 5-year average of $74.9 million and a median of $76.4 million in 2024 define the central range for Accumulated Expenses.
  • Biggest five-year swings in Accumulated Expenses: surged 74.5% in 2022 and later decreased 29.7% in 2023.
  • Year by year, Accumulated Expenses stood at $89.8 million in 2022, then decreased by 28.45% to $64.2 million in 2023, then grew by 24.72% to $80.1 million in 2024, then increased by 19.32% to $95.6 million in 2025, then fell by 11.13% to $85.0 million in 2026.
  • Business Quant data shows Accumulated Expenses for PCRX at $85.0 million in Q1 2026, $95.6 million in Q4 2025, and $79.6 million in Q3 2025.